Ishita Drugs & Industries Ltd (ISHITADR)

Loading page…

Ishita Drugs & Industries Ltd (ISHITADR) · mywealthgrid

About

Ishita Drugs & Industries Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹23 Cr

P/E

26.3×

P/B

2.0×

Dividend yield

ROE

ROCE

10.1%

Debt / equity

0.01

OPM

5.3%

EPS (TTM)

₹2.9

Book value

₹38.7

52-week high

—

52-week low

—

2,067 historical price candles were omitted because the exchange source has not been verified.

₹76.2+5.8%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 19×

Cons

−Low return on equity of 7.7% (3-yr avg)
−Thin operating margin of 5.3%
−Profit declined 1.2% a year over the last 5 years
−Modest revenue growth of 1% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

43/100

Business quality: 45
Growth: 26
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	7	7	9	15	14	14	12	15	15	15
COGS	—	-5	-6	-11	10	10	9	11	11	10
Gross profit	—	—	—	—	4	4	4	4	4	4
	7	11	15	26	3	3	3	3	3	4
	0	0	1	1	1	1	1	1	1	1
OPM %	3.8%	6.7%	5.5%	5.1%	6.6%	7.7%	6.3%	6%	6.7%	5.3%
Depreciation	0	0	0	0	0	0	0	0	0	0
Interest	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0	0	0
Profit before tax	0	0	0	1	1	1	1	1	1	1
Tax	—	0	0	0	0	0	0	0	0	0
Tax %	—	27.3%	21.7%	23.9%	21%	23.1%	25.6%	24.2%	25%	27.8%
	0	0	0	1	1	1	1	1	1	1
PAT margin %	2%	3.6%	3.9%	3.7%	6%	5.7%	4.8%	4.9%	5.8%	5.3%
EPS (₹)	—	0.8	1.2	1.8	2.8	—	—	—	2.9	2.6
EPS adjusted (₹)	—	—	—	—	2.8	2.7	1.9	2.5	2.9	2.6
Annual report	Annual report for Mar 2016	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	3	3	3	3	3	3
Reserves	5	6	6	7	8	9
	0	0	1	0	4	0
	1	3	1	1	2	1
Total equity & liabilities	9	11	11	11	16	13
	1	1	1	1	1	1
CWIP	0	0	0	0	0	2
Investments	3	4	3	3	4	4
	5	6	7	7	12	6
Total assets	9	11	11	11	16	13

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	26.3%	27.8%	29.1%	25.7%	28.7%	29.7%
EBITDA margin %	5.5%	5.1%	6.6%	7.7%	6.3%	6%	6.7%	5.3%
EBIT margin %	3.7%	3.8%	5.5%	6.8%	5.2%	5.3%	5.9%	4.6%
PAT margin %	3.9%	3.7%	6%	5.7%	4.8%	4.9%	5.8%	5.3%
Working capital
Receivable days	—	—	40	14	54	17	46	25
Inventory days	—	—	23	35	68	34	152	33
Payable days	—	—	35	73	37	15	32	20
NWC days	—	—	28	-24	86	36	166	38
Leverage
Current ratio	—	—	5.59	3.82	4.61	11.1	2.77	9.64
Debt to EBITDA	—	—	0	0	1.26	0	3.9	0.1
Debt to equity	—	—	0	0	0.1	0	0.36	0.01
Interest coverage	8.3	25	36	53.5	16.6	12	17.6	19
Asset turnover	—	—	1.51	1.25	1.06	1.41	0.92	1.16
Return ratios
Return on assets %	—	—	9%	7.1%	5.1%	6.9%	5.3%	6.2%
Return on capital employed %	—	—	13.8%	13%	9.3%	11.3%	11.8%	10.1%
Return on equity %	—	—	10.7%	9.3%	6.3%	7.6%	8.1%	6.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	49.38%	49.38%	49.42%	49.8%	49.8%	49.84%	49.91%	49.92%	49.96%	50.04%	50.04%	50.04%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	50.62%	50.62%	50.58%	50.2%	50.2%	50.16%	50.09%	50.08%	50.04%	49.96%	49.96%	49.96%
No. of shareholders	—	—	—	—	—	—	—	—	5,320	5,263	5,194	5,146

Promoter holding up 0.66 percentage points since Sep 2023.

42 deals · 9 Dec 2021 – 1 Oct 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
1 Oct 2026	GAURAV NARESHMAL LODHA	Bulk	BSE	Sell	17,000	₹71.01	₹0.12 Cr
1 Oct 2026	RAJAN MALHOTRA	Bulk	BSE	Buy	15,799	₹71.01	₹0.11 Cr
15 Sept 2025	ISHITA PHARMACEUTICALS	Bulk	BSE	Buy	25,334	₹76.99	₹0.20 Cr
15 Sept 2025	BHUPESHBHAI VAHLABHAI PATEL	Bulk	BSE	Sell	24,997	₹77.00	₹0.19 Cr
11 Sept 2025	USHA JAWAHARLAL KALRO	Bulk	BSE	Sell	22,689	₹77.58	₹0.18 Cr
11 Sept 2025	USHA JAWAHARLAL KALRO	Bulk	BSE	Buy	22,689	₹75.19	₹0.17 Cr
11 Sept 2025	BHUPESHBHAI VAHLABHAI PATEL	Bulk	BSE	Sell	20,200	₹75.34	₹0.15 Cr
25 Nov 2024	PUNEET MITTAL HUF	Bulk	BSE	Sell	25,714	₹89.15	₹0.23 Cr
25 Nov 2024	PUNEET MITTAL HUF	Bulk	BSE	Buy	25,714	₹88.28	₹0.23 Cr
25 Nov 2024	RAJAN MALHOTRA	Bulk	BSE	Buy	18,421	₹83.12	₹0.15 Cr

1–10 of 42

1 / 5

Mr. Jagdishprasad Agrawal GokulchandManaging Director
Mr. Arvind SapkalNon-Executive Independent Director
Mrs. Abha Agrawal JagdishprasadNon-Executive Promoter Director
Ms. Dhwani Jaspalsingh SolankiNon - Executive Independent Director
Mr. Sumit Jagdishprasad AgarwalChief Financial Officer
Miss. Srushti PandyaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Ishita Drugs & Industries Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results8 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

14 announcementsExport CSV

30 Sept 2026, 4:50 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

22 Sept 2026, 5:51 pmCompany Update

Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Availing Credit Facilities From Bank

General PDF

22 Sept 2026, 3:27 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting Held On 22Nd September, 2026

Outcome of Board Meeting PDF

18 Sept 2026, 6:19 pmBoard Meeting

Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Exchange filing PDF

31 Aug 2026, 2:32 pmCompany Update

Weblink Intimation Letter To The Shareholders

General PDF

27 Aug 2026, 4:01 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

27 Aug 2026, 3:54 pmAGM/EGM

NOTICE OF 33RD ANNUAL GENERAL MEETING (AGM) ALONG WITH THE E-VOTING PERIOD

AGM PDF

27 Aug 2026, 3:47 pmAGM/EGM

INTIMATION OF E- VOTING AS PER THE REGULATION 44 OF SEBI (LODR) REGULATION, 2015

AGM PDF

Date	Category	Subject	Filing
30 Sept 2026, 4:50 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
22 Sept 2026, 5:51 pm	Company Update General	Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Availing Credit Facilities From Bank

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	26.3%	27.8%	29.1%	25.7%	28.7%	29.7%
EBITDA margin %	5.5%	5.1%	6.6%	7.7%	6.3%	6%	6.7%	5.3%
EBIT margin %	3.7%	3.8%	5.5%	6.8%	5.2%	5.3%	5.9%	4.6%
PAT margin %	3.9%	3.7%	6%	5.7%	4.8%	4.9%	5.8%	5.3%
Working capital
Receivable days	—	—	40	14	54	17	46	25
Inventory days	—	—	23	35	68	34	152	33
Payable days	—	—	35	73	37	15	32	20
NWC days	—	—	28	-24	86	36	166	38
Leverage
Current ratio	—	—	5.59	3.82	4.61	11.1	2.77	9.64
Debt to EBITDA	—	—	0	0	1.26	0	3.9	0.1
Debt to equity	—	—	0	0	0.1	0	0.36	0.01
Interest coverage	8.3	25	36	53.5	16.6	12	17.6	19
Asset turnover	—	—	1.51	1.25	1.06	1.41	0.92	1.16
Return ratios
Return on assets %	—	—	9%	7.1%	5.1%	6.9%	5.3%	6.2%
Return on capital employed %	—	—	13.8%	13%	9.3%	11.3%	11.8%	10.1%
Return on equity %	—	—	10.7%	9.3%	6.3%	7.6%	8.1%	6.7%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-1	3	-3	2	-4	4
	2	-1	1	0	-1	-2
	-0	0	1	-1	4	-4
Net cash flow	2	2	-1	1	0	-2
Free cash flow	—	—	-3	2	-4	2
CFO / Operating profit %	-72.8%	282.6%	-381.6%	233%	-364%	509.1%

Ishita Drugs & Industries Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

Announcements

Not in the F&O segment

No fund holdings on record

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Ishita Drugs & Industries Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Not in the F&O segment

Ratio timeline

No fund holdings on record

Board meetings1

Announcements

Annual reports

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1